By analyzing the induction of GILZ, FKBP5 and cAMP levels, our results indicate that the sensitivity to both genomic and non-genomic effects of GCs is decreased in UM and SM patients versus asymptomatic controls. The gene discussed is FKBP5; the disease is systemic mastocytosis.